---
title: "INT MEDICAL plans to invest approximately HKD 283 million to subscribe for about 91.0936 million shares of BRONCUS-B"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/260611190.md"
description: "INT MEDICAL plans to subscribe for approximately 91.0936 million shares of BRONCUS-B at a price of HKD 3.11 per share, totaling around HKD 283 million. Upon completion, INT MEDICAL will hold approximately 17.24% of the shares of BRONCUS-B. This subscription will assist INT MEDICAL in its strategic layout in the non-vascular intervention field"
datetime: "2025-10-10T11:04:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260611190.md)
  - [en](https://longbridge.com/en/news/260611190.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260611190.md)
---

# INT MEDICAL plans to invest approximately HKD 283 million to subscribe for about 91.0936 million shares of BRONCUS-B

According to the Zhitong Finance APP, INT MEDICAL (01501) announced that on October 10, 2025 (after trading hours), the company entered into a subscription agreement with BRONCUS, under which BRONCUS conditionally agreed to issue a total of 91,093,613 subscription shares to the company at a subscription price of HKD 3.11 per subscription share, for a total consideration of HKD 283,301,136.43 (excluding transaction costs), subject to the terms and conditions set forth in the subscription agreement.

Upon completion, the company will hold a total of 91,093,613 shares of BRONCUS, which will represent approximately 17.24% of the issued shares of BRONCUS as of the date of this announcement (approximately 17.30% if treasury shares are not counted) and approximately 14.38% of the expanded issued shares of BRONCUS due to this issuance of subscription shares (approximately 14.42% if treasury shares are not counted). The financial performance of BRONCUS will not be consolidated into the group's accounts.

The announcement stated that considering BRONCUS's rich product line in the non-vascular intervention field, the subscription matter could further expand the company's strategic layout in the non-vascular intervention field

### Related Stocks

- [02216.HK](https://longbridge.com/en/quote/02216.HK.md)
- [01501.HK](https://longbridge.com/en/quote/01501.HK.md)

## Related News & Research

- [Comey eyes new 'anti-weaponization' fund: 'I'm guessing I'll be in line'](https://longbridge.com/en/news/286948735.md)
- [Coffee Prices Rebound on Technical Short-Covering](https://longbridge.com/en/news/286941721.md)
- [Trump faces record-low approval on inflation as retirees struggle](https://longbridge.com/en/news/286834439.md)
- [Trump Delivers Confused Rambling After Claiming ’Every Agency' Has 'Scum'](https://longbridge.com/en/news/287086760.md)
- [09:06 ETHarmony Comes to the Massachusetts State House as The Platters® Prepare Their Musical Love Letter to the World](https://longbridge.com/en/news/286918739.md)